|
|
| (One intermediate revision not shown.) |
| Line 3: |
Line 3: |
| | <StructureSection load='4z5r' size='340' side='right'caption='[[4z5r]], [[Resolution|resolution]] 3.00Å' scene=''> | | <StructureSection load='4z5r' size='340' side='right'caption='[[4z5r]], [[Resolution|resolution]] 3.00Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4z5r]] is a 24 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Z5R OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4Z5R FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4z5r]] is a 24 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Z5R OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4Z5R FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3Å</td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">IFNA2, IFNA2A, IFNA2B, IFNA2C ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4z5r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4z5r OCA], [http://pdbe.org/4z5r PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4z5r RCSB], [http://www.ebi.ac.uk/pdbsum/4z5r PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4z5r ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4z5r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4z5r OCA], [https://pdbe.org/4z5r PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4z5r RCSB], [https://www.ebi.ac.uk/pdbsum/4z5r PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4z5r ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/IFNA2_HUMAN IFNA2_HUMAN]] Produced by macrophages, IFN-alpha have antiviral activities. | + | [https://www.uniprot.org/uniprot/IFNA2_HUMAN IFNA2_HUMAN] Produced by macrophages, IFN-alpha have antiviral activities. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 21: |
Line 21: |
| | | | |
| | ==See Also== | | ==See Also== |
| - | *[[Interferon|Interferon]] | + | *[[Interferon 3D structures|Interferon 3D structures]] |
| | *[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | | *[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] |
| | == References == | | == References == |
| Line 27: |
Line 27: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Bosanac, I]] | + | [[Category: Bosanac I]] |
| - | [[Category: Eigenbrot, C]] | + | [[Category: Eigenbrot C]] |
| - | [[Category: Maurer, B]] | + | [[Category: Maurer B]] |
| - | [[Category: Antibody]]
| + | |
| - | [[Category: Cytokine-immune system complex]]
| + | |
| - | [[Category: Interferon]]
| + | |
| Structural highlights
Function
IFNA2_HUMAN Produced by macrophages, IFN-alpha have antiviral activities.
Publication Abstract from PubMed
Interferons-alpha (IFN-alpha) are the expressed gene products comprising thirteen type I interferons with protein pairwise sequence similarities in the 77-96% range. Three other widely expressed human type I interferons, IFN-beta, IFN-kappa and IFN-omega have sequences 29-33%, 29-32% and 56-60% similar to the IFN-alphas, respectively. Type I interferons act on immune cells by producing subtly different immune-modulatory effects upon binding to the extracellular domains of a heterodimeric cell surface receptor composed of IFNAR1 and IFNAR2, most notably anti-viral effects. IFN-alpha has been used to treat infection by hepatitis-virus type C (HCV) and a correlation between hyperactivity of IFN-alpha -induced signaling and systemic lupus erythematosis (SLE), or lupus, has been noted. Anti-IFN-alpha antibodies including rontalizumab have been under clinical study for the treatment of lupus. To better understand the rontalizumab mechanism of action and specificity, we determined the X-ray crystal structure of the Fab fragment of rontalizumab bound to human IFN-alpha2 at 3A resolution and find substantial overlap of the antibody and IFNA2 epitopes on IFN-alpha2. This article is protected by copyright. All rights reserved.
Structural Basis of the Broadly Neutralizing anti-Interferon-alpha Antibody Rontalizumab.,Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C Protein Sci. 2015 Jun 22. doi: 10.1002/pro.2729. PMID:26099203[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. Structural Basis of the Broadly Neutralizing anti-Interferon-alpha Antibody Rontalizumab. Protein Sci. 2015 Jun 22. doi: 10.1002/pro.2729. PMID:26099203 doi:http://dx.doi.org/10.1002/pro.2729
|
